



Discontinuations by baseline CNS metastasis category

	No CNS Metastases	CNS Metastases
Patients, N (%)	15 (60)	10 (40)
Discontinued treatment, n (%)	10 (67)	10 (100)
Adverse event	0 (0)	1 (10)
Death	1 (7)	0 (0)
Physician decision	1 (7)	2 (20)
Progressive disease	8 (53)	7 (70)

Supplementary Figure S1. Patient disposition. CNS, central nervous system; n, number of patients in category; N, number of patients receiving at least 1 dose of ramucirumab plus osimertinib. The data cut-off date was 19-April-2019.